Novartis has signed an exclusive worldwide licensing deal with Abogen Biosciences for its lead mRNA-encoded CD19xCD3 T-cell engager, ABO2203, in a transaction valued at $575 million upfront with potential total milestones of about $7.8 billion. The agreement also includes options to license additional programs built on Abogen’s RNA platform. Abogen positions ABO2203 for in vivo production of a T-cell engager designed to reset B cells through depletion, a strategy that aims to complement existing autoimmune modalities. Novartis said it sees mRNA-encoded engagers as an in vivo approach that could broaden its immunology pipeline. For biotech investors, the deal underscores how large pharmas are increasingly turning to China-based RNA-platform companies to replenish early-stage assets, betting that platform scale can translate into differentiated mechanism opportunities. The transaction remains subject to customary closing conditions and regulatory clearances, but it immediately places ABO2203 among the most capital-heavy immunology licensing efforts tied to mRNA “engineered drug” production.